Catalog # 10-4172
GSK2636771

CAS# 1372540-25-4

2-Methyl-1-(2-methyl-3-(trifluoromethyl)benzyl)-6-morpholino-1H-benzo[d]imidazole-4-carboxylic acid

Lot # FBS4010



GSK2636771 is a potent, selective (>1000-fold over α, 10-fold over δ, and >2000-fold over γ), and orally bioavailable inhibitor of PI3Kß (IC_{50} = 5.2 nM).[1] Active *in vitro* against multiple types of PTEN-deficient cancer cells. GSK2636771 potently blocked migration and invasion of DU145 prostate cancer cells.[2] GSK2636771 has also been identified as a GPR39 agonist.[3]

1) Mateo *et al*. (2017), *A First-in-Human Study of GSK2636771, a Phosphoinositide 3 Kinase Beta-Selective Inhibitor, in Patients with Advanced Solid Tumors*; Clin. Cancer Res. **23** 5981
2) Zhang *et al*. (2018), *Phosphatidylinositol 3-kinase ß and δ isoforms play key roles in metastasis of prostate cancer DU145 cells*; FASEB J. **32** 5967
3) Sato *et al*. (2016); *Discovery and Characterization of Novel GPR39 Agonists Allosterically Modulated by Zinc*, Mol. Pharmacol., **90** 726

PHYSICAL DATA

Molecular Weight:	433.43
Molecular Formula:	$C_{22}H_{22}F_3N_3O_3$
Purity:	>98% by HPLC
	NMR: (Conforms)
Solubility:	DMSO (20 mg/ml)
Physical Description:	Pale yellow solid
Storage and Stability:	Store as supplied at -20°C for up to 2 years from the date of purchase. Solutions in DMSO may be stored at -20°C for up to 3 months.

Focus Biomolecules LLC 400 Davis Drive, Suite 600 Plymouth Meeting PA 19462
www.focusbiomolecules.com